Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Gross Margin (2016 - 2017)

Lisata Therapeutics' Gross Margin history spans 8 years, with the latest figure at 1.51% for Q1 2017.

  • For Q1 2017, Gross Margin fell 1835.0% year-over-year to 1.51%; the TTM value through Mar 2017 reached 7.75%, up 2731.0%, while the annual FY2016 figure was 11.76%, 140.0% up from the prior year.
  • Gross Margin reached 1.51% in Q1 2017 per LSTA's latest filing, down from 9.15% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 19718.99% in Q3 2013 to a low of 97334.9% in Q3 2014.
  • Average Gross Margin over 5 years is 22823.89%, with a median of 7.58% recorded in 2016.
  • Peak YoY movement for Gross Margin: crashed -11705389bps in 2014, then soared 9735323bps in 2015.
  • A 5-year view of Gross Margin shows it stood at 18000.22% in 2013, then crashed by -538bps to 78810.29% in 2014, then dropped by -4bps to 81681.92% in 2015, then surged by 100bps to 9.15% in 2016, then crashed by -116bps to 1.51% in 2017.
  • Per Business Quant, the three most recent readings for LSTA's Gross Margin are 1.51% (Q1 2017), 9.15% (Q4 2016), and 7.58% (Q3 2016).